Lidokain Viatris (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on nerve and cardiac cells, preventing the rapid influx of sodium that initiates action potentials. This stops nerve impulse transmission for anesthesia and reduces abnormal electrical activity in the heart, providing anti‑arrhythmic effects.

The specific dose and infusion rate are determined by the treating physician based on the indication, patient weight, age, and clinical condition. Prescribers tailor the regimen to achieve the desired anesthetic or anti‑arrhythmic effect while monitoring safety.

Lidocaine’s pregnancy category is listed as unknown, and safety data are limited. It should only be used during pregnancy or lactation when the potential benefit justifies any potential risk to the fetus or infant, and under close medical supervision.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Lidocaine has a rapid onset and moderate duration compared with agents such as bupivacaine, which lasts longer but has a slower onset. Its safety profile is well‑established, and it is frequently chosen for procedures requiring quick recovery of sensation, whereas bupivacaine may be preferred for prolonged blocks.

Store the product at ambient temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight and extreme temperatures. Inspect the container for any breach before use and discard any solution that appears discoloured or particulate.

Lidokain Viatris is supplied as a sterile injectable solution for intravenous administration. It is typically given as a slow bolus or continuous infusion under continuous cardiac and hemodynamic monitoring, according to the clinical protocol established by the prescriber.

The most critical adverse events include severe allergic reactions (anaphylaxis), cardiac conduction disturbances such as heart block or ventricular arrhythmias, central nervous system toxicity leading to seizures, methemoglobinemia, and profound hypotension that may progress to cardiac arrest.

Patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics should avoid the product. It is also contraindicated in individuals with severe heart block, uncorrected severe conduction disorders, or those receiving class I antiarrhythmic drugs that could precipitate toxicity.